Integrated Biosciences
Integrated Biosciences is a preclinical biotech company applying AI-driven drug discovery and multimodal aging biology datasets to develop small molecule therapeutics for age-related diseases, with an initial focus on cardiometabolic conditions.
- Company typePrivate
- Founded2023
- HeadquartersRedwood City, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Integrated Biosciences does
Integrated Biosciences is a preclinical-stage biotechnology company developing small molecule therapeutics for age-related diseases, with an initial focus on cardiometabolic conditions. The company's integrated discovery platform combines three components: multimodal aging biological datasets generated across cellular and whole-organism models, proprietary chemistry tools for small molecule design and optimization, and AI models that augment both biology and chemistry workflows. The platform uses AI to propose hypotheses, high-throughput experimental systems to validate them against living systems, and feedback cycles to refine datasets and models. A distinctive technical asset is the company's optogenetics-enabled screening platform, which enables tunable, millisecond- and micron-level control over previously intractable biological systems—highlighted in a landmark Cell publication in September 2025.
The company leverages foundational science from scientific co-founder Prof. Jim Collins at MIT (whose patented technologies have been licensed by over 25 biotech, pharmaceutical, and medical device companies) and is guided by a Scientific Advisory Board that includes 2021 Nobel Laureate David MacMillan (Princeton), systems biology pioneer Uri Alon (Weizmann), former Genentech SVP Wendy Young, and xAI co-founder Tony Wu. Operational leadership includes CSO Dan Anderson (formerly of Eikon, Recursion, Cleave, and Genentech) and Head of AI Alex Peysakhovich. The company has published research in Nature, Nature Aging, Nature Protocols, Cell, and Science, and has developed sub-products including FATE-MAP (a deep learning and mechanistic modeling system for teratogenicity prediction).
Integrated Biosciences is pre-revenue, with a business model centered on advancing a pipeline of small molecule therapeutics toward IND-enabling studies and clinical development, with eventual revenue generation through licensing, co-development partnerships, or acquisition by large pharmaceutical companies. The company has signed a strategic research partnership with LVMH RECHERCHE, extending its platform into luxury and wellness applications. Headquartered in Redwood City, California, with approximately 16 named team members, the company has raised $17.2 million in seed funding led by Sutter Hill Ventures and is actively recruiting across in vivo pharmacology, medicinal chemistry, AI/ML engineering, and lab operations.
Integrated Biosciences firmographics
Firmographics- Name
- Integrated Biosciences
- Legal name
- Integrated Biosciences
- Website
- https://integratedbio.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Integrated Biosciences is a preclinical biotech company applying AI-driven drug discovery and multimodal aging biology datasets to develop small molecule therapeutics for age-related diseases, with an initial focus on cardiometabolic conditions.
- Ownership category
- akta.pro rank
Integrated Biosciences industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Integrated Biosciences is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Integrated Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Therapeutic Drug Development: Pre-revenue biotech company developing a pipeline of novel small molecule therapeutics targeting age-related diseases (cardiometabolic disease focus). Revenue will be generated through clinical development and eventual product commercialization, or through licensing/partnership deals with large pharmaceutical companies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Integrated Biosciences product offering
Product offeringCore offering
Integrated Biosciences is a clinical-stage biotech that discovers and develops small molecule therapeutics for age-related diseases, with an initial focus on cardiometabolic disease. Its core offering is a unified discovery engine built on multimodal aging biological datasets, proprietary chemistry tools, and AI-driven hypothesis generation, validated through high-throughput optogenetics-enabled screening of living systems. The company monetizes its pipeline through pharmaceutical licensing deals, co-development partnerships, and potential acquisition rather than direct drug sales.
Product overview
Integrated Biosciences is an aging science company offering a unified drug discovery platform that combines three core components: aging biological datasets (differentiated datasets across cellular and whole-organism models), drug design tools (novel chemistry for small molecule optimization), and AI capabilities (augmenting dual biology and chemistry platforms). The platform uses feedback cycles where AI models propose hypotheses, high-throughput experimental platforms validate them against living systems, and experimental results improve datasets and models. The company is advancing a pipeline of small molecule therapeutics targeting age-related pathways, with initial focus on cardiometabolic disease. Research has been published in Nature, Nature Aging, Nature Protocols, and Cell, with key innovations including an optogenetics-enabled screening platform for novel drug discovery and the FATE-MAP system for teratogenicity prediction.
Differentiator
Problem solved
Functional benefit
Products and services
- Integrated Drug Discovery Platform A multimodal discovery engine combining aging biological datasets, novel chemistry tools, and AI models to propose hypotheses, validate them against living systems through high-throughput experimental platforms, and iterate to discover small molecule therapeutics for age-related diseases.
- Small Molecule Therapeutics Pipeline Portfolio of small molecule therapeutics targeting age-related pathways, with initial focus on cardiometabolic disease, developed using the integrated platform combining aging biology, chemistry, and AI.
- Optogenetics-enabled Screening Platform First-of-a-kind optogenetic screening platform enabling tunable, millisecond- and micron-level control over biological systems, supporting discovery of integrated stress response modulators and other novel therapeutics.
- FATE-MAP Deep learning and mechanistic modeling system that predicts teratogenicity and human gastrulation failure modes, integrating deep learning with mechanistic modeling for teratogenicity prediction.
Quantifiable outcome
- Optogenetics-enabled screening platform discovered integrated stress response modulators with tunable, millisecond-level control over biological systems — published in Cell, September 2025.
- +1 more outcomes
Companies that use Integrated Biosciences
Customer profileSegments2 records
Ideal customer profiles2 records
Integrated Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
Integrated Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LVMH RECHERCHEcoreStrategic research partnership between LVMH RECHERCHE and Integrated Biosciences. This partnership, announced alongside other industry deals (e.g., Rubedo Life Sciences and Beiersdorf AG), positions Integrated Biosciences at the intersection of longevity science and luxury goods/wellness applications.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Integrated Biosciences competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Recursion is a publicly traded AI-driven drug discovery company combining high-throughput biology with machine learning to discover therapeutics. Directly comparable to Integrated Bio in platform approach (AI + wet-lab validation), target breadth, and pipeline-stage biotech profile; Integrated Bio's CSO Dan Anderson previously served as VP of Biology at Recursion.
- Insitro: Insitro applies machine learning to drug discovery and development using proprietary induced pluripotent stem cell-derived disease models and high-throughput biology. Directly comparable to Integrated Bio's combination of multimodal biological datasets and AI for therapeutic discovery, with a similar mix of in-house pipeline and pharma partnerships.
- Isomorphic Labs: Isomorphic Labs (Alphabet-owned) applies DeepMind's AI to drug discovery, partnering with pharma on novel therapeutics. Directly comparable as an AI-first drug discovery platform with a focus on novel small molecule design, though backed by substantially greater resources than Integrated Bio.
- Eikon Therapeutics: Eikon combines single-molecule tracking instrumentation with AI for live-cell biology drug discovery. Directly comparable as a tech-forward biotech pursuing novel therapeutics; Integrated Bio's CSO Dan Anderson was previously CSO at Eikon, giving deep operational familiarity with this peer.
- Schrödinger: Schrödinger operates a physics-based computational platform for small molecule drug discovery, combining molecular simulation with AI and operating its own pipeline alongside software and partnership revenues. Comparable to Integrated Bio's AI/chemistry integration for small molecule design.
- Atomwise: Atomwise applies AI (AtomNet) to small molecule design and discovery, partnering with pharma across multiple therapeutic areas. Comparable to Integrated Bio as a seed/early-stage AI-driven small molecule platform with a pharma partnership go-to-market.
- BioAge Labs: BioAge is a clinical-stage biotech using AI and systems biology to discover therapeutics that target the mechanisms of aging. Highly comparable as a platform-driven aging biotech advancing small molecule drug candidates into the clinic.
- Unity Biotechnology: Unity Biotechnology is a clinical-stage biotech developing senolytic therapeutics to treat age-related diseases. Comparable to Integrated Bio's age-related small molecule focus, particularly the senolytic modality, though at a more advanced clinical stage.
Broad incumbents
- Calico Life Sciences: Calico (Alphabet-backed) is a well-funded R&D biotech whose central mission is understanding the biology of aging and developing therapeutics for age-related disease. Comparable to Integrated Bio's aging-biology focus but operating with substantially greater scale and Alphabet funding.
- Altos Labs: Altos Labs pursues cellular rejuvenation programming to restore cell health and reverse disease, with a focus on aging biology. Comparable to Integrated Bio's aging-biology mission and likely competitive for the same talent and partnership opportunities, though substantially better funded.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Integrated Biosciences social profiles
Digital presenceIntegrated Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Integrated Biosciences leadership team
Management profileNumber of profiles
Profiles15 records
Integrated Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Integrated Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Integrated Biosciences
What does Integrated Biosciences do?
Integrated Biosciences is a clinical-stage biotech that discovers and develops small molecule therapeutics for age-related diseases, with an initial focus on cardiometabolic disease. Its core offering is a unified discovery engine built on multimodal aging biological datasets, proprietary chemistry tools, and AI-driven hypothesis generation, validated through high-throughput optogenetics-enabled screening of living systems. The company monetizes its pipeline through pharmaceutical licensing deals, co-development partnerships, and potential acquisition rather than direct drug sales.
Is Integrated Biosciences a public or private company?
Integrated Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Integrated Biosciences founded?
Integrated Biosciences was founded in 2023. It employs 11 to 50 people.
Where is Integrated Biosciences based?
Integrated Biosciences is headquartered in Redwood City, United States, in the North America region.
How does Integrated Biosciences make money?
One revenue line is on record: therapeutic Drug Development.
Who are Integrated Biosciences's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Isomorphic Labs, Eikon Therapeutics, Schrödinger, Atomwise, BioAge Labs and Unity Biotechnology. Broad incumbents are Calico Life Sciences and Altos Labs.
Does Integrated Biosciences have an API?
No public API is recorded for Integrated Biosciences.
What industry is Integrated Biosciences in?
Integrated Biosciences's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 8731.